Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review
Abstract Off-label use of dalbavancin for deep-seated and endovascular infections has been increasing. We performed a scoping review to evaluate the evidence for use of multiple-dose dalbavancin regimens as the predominant therapy for these indications. Predominant therapy was defined as use of dalb...
Gespeichert in:
| Veröffentlicht in: | Open Forum Infectious Diseases 2021-11, Vol.8 (11), p.ofab486-ofab486, Article 486 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | ofab486 |
|---|---|
| container_issue | 11 |
| container_start_page | ofab486 |
| container_title | Open Forum Infectious Diseases |
| container_volume | 8 |
| creator | Cooper, Margaret M Preslaski, Candice R Shihadeh, Katherine C Hawkins, Kellie L Jenkins, Timothy C |
| description | Abstract
Off-label use of dalbavancin for deep-seated and endovascular infections has been increasing. We performed a scoping review to evaluate the evidence for use of multiple-dose dalbavancin regimens as the predominant therapy for these indications. Predominant therapy was defined as use of dalbavancin without other concurrent antibiotics for more than half of the total treatment duration. Fifteen publications were identified; 2 were small, open-label randomized controlled trials and the remainder were retrospective observational studies or case reports. A total of 144 cases from these publications met eligibility criteria for inclusion in this review. Types of infections included osteoarticular infections, catheter-related or complicated bloodstream infections, and infective endocarditis. Overall, the evidence for use of multiple-dose regimens of dalbavancin for deep-seated and endovascular infections is limited by a paucity of data from controlled trials, heterogeneity of dosing regimens, and a lack of standardized clinical outcomes.
Evidence for the use of multiple-dose dalbavancin regimens as the predominant therapy for deep-seated or endovascular infections is limited. Limitations of the literature include a paucity of data from controlled trials and heterogeneity of dosing regimens and outcome reporting. |
| doi_str_mv | 10.1093/ofid/ofab486 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_webof</sourceid><recordid>TN_cdi_webofscience_primary_000732746200021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A776147364</galeid><oup_id>10.1093/ofid/ofab486</oup_id><sourcerecordid>A776147364</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-937e37fd5ef2c5401a118bde9b8dfe3c65366d7b115cd8f8efbdc3abb269cfa13</originalsourceid><addsrcrecordid>eNqNUV1rFDEUHUSxpfbNH5A3BZ2aj5lkxgdh2a1aqCi2PodMcrONzCRjktki_nmz7FL0RSSQXO4953BuTlU9J_iC4J69CdaZcqmh6fij6pQy2tVd34rHf9Qn1XlK3zHGhOAWi_5pdcIawTpM29Pq16dlzG4eod6EBGijxkHtlNfOo6-wdRP4hFRC-Q7QlwgmTM4rn9FtBJXLMKNg0QZgrm9KAwwKEV16E3Yq6WVUEV15Czq74NNbtEI3OszOb4v0zsH9s-qJVWOC8-N7Vn17f3m7_lhff_5wtV5d17rhONc9E8CENS1YqtsGE0VINxjoh85YYJq3jHMjBkJabTrbgR2MZmoYKO-1VYSdVe8OuvMyTGB0sR3VKOfoJhV_yqCc_Hvi3Z3chp3sWk4b3heBl0eBGH4skLKcXNIwjspDWJKkbd_QnpY_LdCLA3SrRpDO21AUdTkGJqeDB-tKfyUEJyUD3hTC6wNBx5BSBPvgi2C5z1juM5bHjAv81QF-D0OwSTvwGh4oJWTBqGg4LRXdb979P3rtstontQ6Lz4X64kANy_xvS78B7hzLJg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2594292738</pqid></control><display><type>article</type><title>Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Oxford University Press (Open Access Collection)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><creator>Cooper, Margaret M ; Preslaski, Candice R ; Shihadeh, Katherine C ; Hawkins, Kellie L ; Jenkins, Timothy C</creator><creatorcontrib>Cooper, Margaret M ; Preslaski, Candice R ; Shihadeh, Katherine C ; Hawkins, Kellie L ; Jenkins, Timothy C</creatorcontrib><description>Abstract
Off-label use of dalbavancin for deep-seated and endovascular infections has been increasing. We performed a scoping review to evaluate the evidence for use of multiple-dose dalbavancin regimens as the predominant therapy for these indications. Predominant therapy was defined as use of dalbavancin without other concurrent antibiotics for more than half of the total treatment duration. Fifteen publications were identified; 2 were small, open-label randomized controlled trials and the remainder were retrospective observational studies or case reports. A total of 144 cases from these publications met eligibility criteria for inclusion in this review. Types of infections included osteoarticular infections, catheter-related or complicated bloodstream infections, and infective endocarditis. Overall, the evidence for use of multiple-dose regimens of dalbavancin for deep-seated and endovascular infections is limited by a paucity of data from controlled trials, heterogeneity of dosing regimens, and a lack of standardized clinical outcomes.
Evidence for the use of multiple-dose dalbavancin regimens as the predominant therapy for deep-seated or endovascular infections is limited. Limitations of the literature include a paucity of data from controlled trials and heterogeneity of dosing regimens and outcome reporting.</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofab486</identifier><identifier>PMID: 34738025</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Care and treatment ; Dalbavancin ; Editor's Choice ; Health aspects ; Immunology ; Infection ; Infectious Diseases ; Infective endocarditis ; Life Sciences & Biomedicine ; Methicillin ; Microbiology ; Respiratory agents ; Review ; Rifamycins ; Science & Technology</subject><ispartof>Open Forum Infectious Diseases, 2021-11, Vol.8 (11), p.ofab486-ofab486, Article 486</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2021</rights><rights>COPYRIGHT 2021 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>12</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000732746200021</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c460t-937e37fd5ef2c5401a118bde9b8dfe3c65366d7b115cd8f8efbdc3abb269cfa13</citedby><cites>FETCH-LOGICAL-c460t-937e37fd5ef2c5401a118bde9b8dfe3c65366d7b115cd8f8efbdc3abb269cfa13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562469/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562469/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,1605,2115,27929,27930,39263,53796,53798</link.rule.ids></links><search><creatorcontrib>Cooper, Margaret M</creatorcontrib><creatorcontrib>Preslaski, Candice R</creatorcontrib><creatorcontrib>Shihadeh, Katherine C</creatorcontrib><creatorcontrib>Hawkins, Kellie L</creatorcontrib><creatorcontrib>Jenkins, Timothy C</creatorcontrib><title>Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review</title><title>Open Forum Infectious Diseases</title><addtitle>OPEN FORUM INFECT DI</addtitle><description>Abstract
Off-label use of dalbavancin for deep-seated and endovascular infections has been increasing. We performed a scoping review to evaluate the evidence for use of multiple-dose dalbavancin regimens as the predominant therapy for these indications. Predominant therapy was defined as use of dalbavancin without other concurrent antibiotics for more than half of the total treatment duration. Fifteen publications were identified; 2 were small, open-label randomized controlled trials and the remainder were retrospective observational studies or case reports. A total of 144 cases from these publications met eligibility criteria for inclusion in this review. Types of infections included osteoarticular infections, catheter-related or complicated bloodstream infections, and infective endocarditis. Overall, the evidence for use of multiple-dose regimens of dalbavancin for deep-seated and endovascular infections is limited by a paucity of data from controlled trials, heterogeneity of dosing regimens, and a lack of standardized clinical outcomes.
Evidence for the use of multiple-dose dalbavancin regimens as the predominant therapy for deep-seated or endovascular infections is limited. Limitations of the literature include a paucity of data from controlled trials and heterogeneity of dosing regimens and outcome reporting.</description><subject>Care and treatment</subject><subject>Dalbavancin</subject><subject>Editor's Choice</subject><subject>Health aspects</subject><subject>Immunology</subject><subject>Infection</subject><subject>Infectious Diseases</subject><subject>Infective endocarditis</subject><subject>Life Sciences & Biomedicine</subject><subject>Methicillin</subject><subject>Microbiology</subject><subject>Respiratory agents</subject><subject>Review</subject><subject>Rifamycins</subject><subject>Science & Technology</subject><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>HGBXW</sourceid><recordid>eNqNUV1rFDEUHUSxpfbNH5A3BZ2aj5lkxgdh2a1aqCi2PodMcrONzCRjktki_nmz7FL0RSSQXO4953BuTlU9J_iC4J69CdaZcqmh6fij6pQy2tVd34rHf9Qn1XlK3zHGhOAWi_5pdcIawTpM29Pq16dlzG4eod6EBGijxkHtlNfOo6-wdRP4hFRC-Q7QlwgmTM4rn9FtBJXLMKNg0QZgrm9KAwwKEV16E3Yq6WVUEV15Czq74NNbtEI3OszOb4v0zsH9s-qJVWOC8-N7Vn17f3m7_lhff_5wtV5d17rhONc9E8CENS1YqtsGE0VINxjoh85YYJq3jHMjBkJabTrbgR2MZmoYKO-1VYSdVe8OuvMyTGB0sR3VKOfoJhV_yqCc_Hvi3Z3chp3sWk4b3heBl0eBGH4skLKcXNIwjspDWJKkbd_QnpY_LdCLA3SrRpDO21AUdTkGJqeDB-tKfyUEJyUD3hTC6wNBx5BSBPvgi2C5z1juM5bHjAv81QF-D0OwSTvwGh4oJWTBqGg4LRXdb979P3rtstontQ6Lz4X64kANy_xvS78B7hzLJg</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Cooper, Margaret M</creator><creator>Preslaski, Candice R</creator><creator>Shihadeh, Katherine C</creator><creator>Hawkins, Kellie L</creator><creator>Jenkins, Timothy C</creator><general>Oxford University Press</general><general>Oxford Univ Press</general><scope>TOX</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20211101</creationdate><title>Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review</title><author>Cooper, Margaret M ; Preslaski, Candice R ; Shihadeh, Katherine C ; Hawkins, Kellie L ; Jenkins, Timothy C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-937e37fd5ef2c5401a118bde9b8dfe3c65366d7b115cd8f8efbdc3abb269cfa13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Care and treatment</topic><topic>Dalbavancin</topic><topic>Editor's Choice</topic><topic>Health aspects</topic><topic>Immunology</topic><topic>Infection</topic><topic>Infectious Diseases</topic><topic>Infective endocarditis</topic><topic>Life Sciences & Biomedicine</topic><topic>Methicillin</topic><topic>Microbiology</topic><topic>Respiratory agents</topic><topic>Review</topic><topic>Rifamycins</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cooper, Margaret M</creatorcontrib><creatorcontrib>Preslaski, Candice R</creatorcontrib><creatorcontrib>Shihadeh, Katherine C</creatorcontrib><creatorcontrib>Hawkins, Kellie L</creatorcontrib><creatorcontrib>Jenkins, Timothy C</creatorcontrib><collection>Access via Oxford University Press (Open Access Collection)</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Open Forum Infectious Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cooper, Margaret M</au><au>Preslaski, Candice R</au><au>Shihadeh, Katherine C</au><au>Hawkins, Kellie L</au><au>Jenkins, Timothy C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review</atitle><jtitle>Open Forum Infectious Diseases</jtitle><stitle>OPEN FORUM INFECT DI</stitle><date>2021-11-01</date><risdate>2021</risdate><volume>8</volume><issue>11</issue><spage>ofab486</spage><epage>ofab486</epage><pages>ofab486-ofab486</pages><artnum>486</artnum><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract
Off-label use of dalbavancin for deep-seated and endovascular infections has been increasing. We performed a scoping review to evaluate the evidence for use of multiple-dose dalbavancin regimens as the predominant therapy for these indications. Predominant therapy was defined as use of dalbavancin without other concurrent antibiotics for more than half of the total treatment duration. Fifteen publications were identified; 2 were small, open-label randomized controlled trials and the remainder were retrospective observational studies or case reports. A total of 144 cases from these publications met eligibility criteria for inclusion in this review. Types of infections included osteoarticular infections, catheter-related or complicated bloodstream infections, and infective endocarditis. Overall, the evidence for use of multiple-dose regimens of dalbavancin for deep-seated and endovascular infections is limited by a paucity of data from controlled trials, heterogeneity of dosing regimens, and a lack of standardized clinical outcomes.
Evidence for the use of multiple-dose dalbavancin regimens as the predominant therapy for deep-seated or endovascular infections is limited. Limitations of the literature include a paucity of data from controlled trials and heterogeneity of dosing regimens and outcome reporting.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>34738025</pmid><doi>10.1093/ofid/ofab486</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2328-8957 |
| ispartof | Open Forum Infectious Diseases, 2021-11, Vol.8 (11), p.ofab486-ofab486, Article 486 |
| issn | 2328-8957 2328-8957 |
| language | eng |
| recordid | cdi_webofscience_primary_000732746200021 |
| source | DOAJ Directory of Open Access Journals; Access via Oxford University Press (Open Access Collection); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central |
| subjects | Care and treatment Dalbavancin Editor's Choice Health aspects Immunology Infection Infectious Diseases Infective endocarditis Life Sciences & Biomedicine Methicillin Microbiology Respiratory agents Review Rifamycins Science & Technology |
| title | Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T20%3A01%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multiple-Dose%20Dalbavancin%20Regimens%20as%20the%20Predominant%20Treatment%20of%20Deep-Seated%20or%20Endovascular%20Infections:%20A%20Scoping%20Review&rft.jtitle=Open%20Forum%20Infectious%20Diseases&rft.au=Cooper,%20Margaret%20M&rft.date=2021-11-01&rft.volume=8&rft.issue=11&rft.spage=ofab486&rft.epage=ofab486&rft.pages=ofab486-ofab486&rft.artnum=486&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofab486&rft_dat=%3Cgale_webof%3EA776147364%3C/gale_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2594292738&rft_id=info:pmid/34738025&rft_galeid=A776147364&rft_oup_id=10.1093/ofid/ofab486&rfr_iscdi=true |